MedTrace Logo

Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer

NCT03577808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-08-20

No results posted yet for this study

Summary

Patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids model from the pre-treatment biopsies and expose organoids to irradiation and the same chemotherapy drugs. The sensitivity of irradiation and chemotherapy drugs will be tested in the organoids model. Here, the investigators will launch the observational clinical trial to validate whether the organoids could predict the clinical outcome in locally advanced rectal cancer patients underwent neoadjuvant chemoradiation.

Conditions

Interventions

OTHER

Biopsy

Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.

Sponsors & Collaborators

  • Zhen Zhang

    lead OTHER

Principal Investigators

  • Zhen Zhang, MD · Fudan University

  • Guoqiang Hua, PhD · Institute of Radiation Medicine, Fudan University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-17
Primary Completion
2020-08-01
Completion
2020-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03577808 on ClinicalTrials.gov